Markers of renal cell carcinoma stem cells

Abstract

Huang Liangliang, Wang Delin. Markers of renal cell carcinoma stem cells[J]. Journal of International Oncology, 2014, 41(8): 668-671.

［1］ Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013［J］. CA Cancer J Clin, 2013, 63(1): 11-30. ［2］ Chen L, Kasai T, Li Y, et al. A model of cancer stem cells derived from mouse induced pluripotent stem cells［J］. PLoS One, 2012, 7(4): e33544. ［3］ Kellner S, Kikyo N. Transcriptional regulation of the Oct4 gene, a master gene for pluripotency［J］. Histol Histopathol, 2010, 25(3): 405-412. ［4］ Gupta S, Verfaillie C, Chmielewski D, et al. Isolation and characterization of kidneyderived stem cells［J］. J American Soc Nephrol, 2006, 17(11): 3028-3040. ［5］ Looijenga LH, Stoop H, de Leeuw HP, et al. POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors［J］. Cancer Res, 2003, 63(9): 2244-2250. ［6］ Raman JD, Mongan NP, Liu L, et al. Decreased expression of the human stem cell marker, Rex1 (zfp42), in renal cell carcinoma［J］. Carcinogenesis, 2006, 27(3): 499-507. ［7］ Bussolati B, Moggio A, Collino F, et al. Hypoxia modulates the undifferentiated phenotype of human renal inner medullary CD133＋ progenitors through Oct4/miR145 balance［J］. Am J Physiol Renal Physiol, 2012, 302(1): F116-128. ［8］ Gazda LS, Martis PC, Laramore MA, et al. Treatment of agaroseagarose RENCA macrobeads with docetaxel selects for OCT4(＋) cells with tumorinitiating capability［J］. Cancer Biol Ther, 2013, 14(12): 1147-1157. ［9］ Abad M, Mosteiro L, Pantoja C, et al. Reprogramming in vivo produces teratomas and iPS cells with totipotency features［J］. Nature, 2013, 502(7471): 340-345. ［10］ Yin AH, Miraglia S, Zanjani ED, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells［J］. Blood, 1997, 90(12): 5002-5012. ［11］ Bussolati B, Bruno S, Grange C, et al. Isolation of renal progenitor cells from adult human kidney［J］. Am J Pathol, 2005, 166(2): 545-555. ［12］ Angelotti ML, Ronconi E, Ballerini L, et al. Characterization of renal progenitors committed toward tubular lineage and their regenerative potential in renal tubular injury［J］. Stem Cells, 2012, 30(8): 1714-1725. ［13］ Bruno S, Bussolati B, Grange C, et al. CD133＋ renal progenitor cells contribute to tumor angiogenesis［J］. Am J Pathol, 2006, 169(6): 2223-2235. ［14］ Addla SK, Brown MD, Hart CA, et al. Characterization of the Hoechst 33342 side population from normal and malignant human renal epithelial cells［J］. Am J Physiol Renal Physiol, 2008, 295(3): F680-687. ［15］ Costa WH, Rocha RM, Cunha IW, et al. CD133 immunohistochemical expression predicts progression and cancerrelated death in renal cell carcinoma［J］. World J Urol, 2012, 30(4): 553-558. ［16］ Kim K, Ihm H, Ro JY, et al. Highlevel expression of stem cell marker CD133 in clear cell renal cell carcinoma with favorable prognosis［J］. Oncol Lett, 2011, 2(6): 1095-1100. ［17］ Fonsatti E, Nicolay HJ, Altomonte M, et al. Targeting cancer vasculature via endoglin/CD105: a novel antibodybased diagnostic and therapeutic strategy in solid tumours［J］. Cardiovasc Res, 2010, 86(1): 12-19. ［18］ Bussolati B, Dekel B, Azzarone B, et al. Human renal cancer stem cells［J］. Cancer Lett, 2013, 338(1): 141-146. ［19］ Bussolati B, Bruno S, Grange C, et al. Identification of a tumorinitiating stem cell population in human renal carcinomas［J］. FASEB J, 2008, 22(10): 3696-3705. ［20］ Dubinski W, Gabril M, Iakovlev VV, et al. Assessment of the prognostic significance of endoglin (CD105) in clear cell renal cell carcinoma using automated image analysis［J］. Hum Pathol, 2012, 43(7): 1037-1043. ［21］ Huang B, Huang YJ, Yao ZJ, et al. Cancer stem celllike side population cells in clear cell renal cell carcinoma cell line 769P［J］. PLoS One, 2013, 8(7): e68293. ［22］ Goodell MA, Brose K, Paradis G, et al. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo［J］. J Exp Med, 1996, 183(4): 1797-1806. ［23］ Nishizawa S, Hirohashi Y, Torigoe T, et al. HSP DNAJB8 controls tumorinitiating ability in renal cancer stemlike cells［J］. Cancer Res, 2012, 72(11): 2844-2854. ［24］ Lu J, Cui Y, Zhu J, et al. Biological characteristics of Rh123high stem like cells in a side population of 786O renal carcinoma cells［J］. Oncol Lett, 2013, 5(6): 1903-1908. ［25］ Ratajczak MZ, ZubaSurma E, Kucia M, et al. The pleiotropic effects of the SDF1CXCR4 axis in organogenesis, regeneration and tumorigenesis［J］. Leukemia, 2006, 20(11): 1915-1924. ［26］ Gassenmaier M, Chen D, Buchner A, et al. CXC chemokine receptor 4 is essential for maintenance of renal cell carcinomainitiating cells and predicts metastasis［J］. Stem Cells, 2013, 31(8): 1467-1476. ［27］ Cojoc M, Peitzsch C, Trautmann F, et al. Emerging targets in cancer management: role of the CXCL12/CXCR4 axis［J］. Onco Targets Ther, 2013, 6: 1347-1361. ［28］ Wend P, Holland JD, Ziebold U, et al. Wnt signaling in stem and cancer stem cells［J］. Semin Cell Dev Biol, 2010, 21(8): 855-863. ［29］ Saito N, Fu J, Zheng S, et al. A high notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma tumorinitiating cells［J］. Stem Cells, 2014, 32(1): 301-312. ［30］ Bartucci M, Dattilo R, Moriconi C, et al. TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells［J］. Oncogene, 2014, In press.

[1]	Wei Yongjian, Hu Jinjing, Li Xun.Relationship between CDCA8 and tumor progression as well as that between CDCA8 and stemness maintenance of stem cells[J]. Journal of International Oncology, 2021, 48(4): 216-219.
[2]	Kang Ye, Li Jianyi, Yang Xianghong.Research progress of cancer stem cells in triplenegative breast cancer[J]. Journal of International Oncology, 2019, 46(6): 362-365.
[3]	Wang Huan, Jiang Haiping, Gao yuan, Xu Nong, Yu Xiongfei.Research progress of anti PD-1/PD-L1 immunotherapy biomarkers[J]. Journal of International Oncology, 2019, 46(1): 40-44.
[4]	LIU Hou-Jie, WAN Jing-Hai.Molecular mechanism in malignant progression of meningioma[J]. Journal of International Oncology, 2018, 45(8): 494-498.
[5]	XU Yao-Zong, GU Xiao, WANG Fei, DING Xue-Fei.Molecular mechanisms of castrationresistant prostate cancer progressed from prostate cancer by androgen deprivation treatment[J]. Journal of International Oncology, 2018, 45(8): 506-509.
[6]	Wang Tuo, Li Guixiang.Research progress of circulating tumor DNA detection in radiotherapy[J]. Journal of International Oncology, 2018, 45(6): 352-354.
[7]	Liu Hengyao, Zhao Guoli, Wang Fuwen, Cai Haibo, Zhang Yueying..Notch signaling pathway in lung cancer and lung cancer stem cells and its inhibitors[J]. Journal of International Oncology, 2018, 45(4): 250-252.
[8]	Wang Axiang, Gao Quanli.Predictive biomarkers of efficacy to PD-1/PD-L1 inhibitors[J]. Journal of International Oncology, 2018, 45(12): 751-755.
[9]	PENG Yong-Hua, PENG Li, LIANG Zhi-Man, ZHANG Xing-Mei.Application of aptamer in the study of cancer stem cells[J]. Journal of International Oncology, 2017, 44(8): 672-675.
[10]	Tong Yalan, Han Tao, Liu Zhongzheng, Yuan Gang, Liang Yan, Liu Zhaozhe, Xie Xiaodong, Yue Chengshan.Therapeutic resistance of breast cancer stem cells and its related signaling pathway[J]. Journal of International Oncology, 2017, 44(7): 544-546.
[11]	Guo Chongyong, Li Yongmei, Li Bocheng, Zhou Ling, Zhang Jian, Jia Zongshi.Expressions and clinical significances of aldehyde dehydrogenase 1 and transforming growth factor-β2 in triple negative breast cancer[J]. Journal of International Oncology, 2017, 44(11): 801-805.
[12]	郑佩.Wnt/β-catenin signaling pathway and cancer stem cells[J]. Journal of International Oncology, 2017, 44(11): 853-855.
[13]	GAN Ya-Ping, GUO Xiao-Hua, ZHANG Jun-Yu, XU Qing-Qing, WU Jiang, WANG Ren-Yong, QIU Min, JIANG Ru-Gang, LIU Fu-Xing, NING Zhi-Feng.Construction of colonic cancer drugresistant cell line COLO and its relationship with tumor stem cells[J]. Journal of International Oncology, 2016, 43(8): 646-650.
[14]	Cui Jinyuan, Tao Kaixiong.Predictive biomarkers in tumor treatment by blocking PD-1/PD-L1 pathway[J]. Journal of International Oncology, 2016, 43(6): 452-454.
[15]	Liu Liguo, Yan Xuebing, Shan Zezhi, Jin Zhiming.Advances of cancer stem cell markers in colorectal cancer[J]. Journal of International Oncology, 2016, 43(6): 468-471.

Markers of renal cell carcinoma stem cells

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments